Literature DB >> 2121677

A novel model of solitary hepatic tumor in rats using ascites hepatoma AH13: suitability for chemotherapeutic studies.

Y Tamura1, Y Sakata, K Tsushima, S Narushima, Y Yamada, H Ogasawara, T Ito, S Saitoh, H Suzuki, Y Yoshida.   

Abstract

A highly reproducible model of a solitary hepatic tumor in rats using ascites hepatoma AH13 has been developed using a two-step method which was suitable for quantitative chemotherapeutic studies. Diffuse hepatic metastases were induced first by inoculation of three different ascites hepatomas, AH13, AH130 and AH7974 into the portal vein in a dose-dependent fashion. Second, the induced hepatic tumor (3 x 10(7) cells) was minced into 1 x 1 x 4 mm fragments and implanted in the liver of normal rats. In this procedure, the AH13 strain proved best suited for the generation of a solitary hepatic tumor. The growth of the solitary liver tumor using AH13 was highly reproducible. To demonstrate the suitability of this solitary hepatic tumor model for the evaluation of chemotherapy, the tumor-burdened rats were treated with adriamycin (ADR) and mitomycin C (MMC). The reduction in tumor size was proportional to dosage, and the statistical significance of the differences between the treatment group and control group was proportional to dosage. A synergistic effect of ADR and MMC on the tumor also was demonstrated. This model should prove to be a useful tool for the testing of newly developed treatments of hepatic cancer.

Entities:  

Mesh:

Year:  1990        PMID: 2121677      PMCID: PMC5917973          DOI: 10.1111/j.1349-7006.1990.tb03344.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  30 in total

1.  Ploidy distribution in experimental liver carcinogenesis in mice.

Authors:  H E Danielsen; H B Steen; T Lindmo; A Reith
Journal:  Carcinogenesis       Date:  1988-01       Impact factor: 4.944

2.  In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue.

Authors:  L M de Brauw; C J van de Velde; U R Tjaden; E A de Bruijn; A V Bell; J Hermans; A Zwaveling
Journal:  J Surg Res       Date:  1988-02       Impact factor: 2.192

3.  A murine ovarian tumor with unique metastasizing capacity.

Authors:  G Alessandri; R Giavazzi; P Falautano; F Spreafico; S Garattini; A Mantovani
Journal:  Eur J Cancer       Date:  1981-06       Impact factor: 9.162

4.  Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

Authors:  R B Cameron; J K McIntosh; S A Rosenberg
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

5.  Factor from rat liver with antiinvasive potential on rat ascites hepatoma cells.

Authors:  K Shinkai; M Mukai; K Komatsu; H Akedo
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

6.  Primary liver cancers in Japan.

Authors: 
Journal:  Cancer       Date:  1980-05-15       Impact factor: 6.860

7.  Reduced incidence of hepatic metastases by perioperative treatment with recombinant human interleukin-2.

Authors:  J L Weese; S E Emoto; P M Sondel
Journal:  Dis Colon Rectum       Date:  1987-07       Impact factor: 4.585

8.  The effect of thrombocytopenia and antiserotonin treatment on the lodgement of circulating tumor cells. A vital fluorescence microscopic, electron microscopic and isotope study in the rat.

Authors:  G Skolnik; L E Ericson; U Bagge
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

9.  Serum and liver glycylproline dipeptidyl aminopeptidase activity in rats with experimental hepatic cancer.

Authors:  J Kojima; M Kanatani; N Nakamura; T Kashiwagi; F Tohjoh; M Akiyama
Journal:  Clin Chim Acta       Date:  1980-10-23       Impact factor: 3.786

10.  Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay.

Authors:  A E Bogden; W R Cobb; D J Lepage; P M Haskell; T A Gulkin; A Ward; D E Kelton; H J Esber
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.